• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

    6/25/25 8:00:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INM alert in real time by email

    Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-term preferred investment option in a private placement priced at-the-market under Nasdaq rules. The short-term preferred investment option to be issued in the offering will be exercisable immediately upon issuance at an exercise price of $2.436 per share and will expire eighteen months from the effective date of the Resale Registration Statement (as defined below).

    H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

    The aggregate gross proceeds to the Company from the offering are expected to be approximately $5 million, before deducting placement agent fees and other offering expenses. The offering is expected to close on or about June 25, 2025, subject to the satisfaction of customary closing conditions. The potential additional gross proceeds to the Company from the short-term preferred investment options, if fully-exercised on a cash basis, will be approximately $4.75 million. No assurance can be given that any of such short-term preferred investment options will be exercised. The Company intends to use the net proceeds from the offering to continue pipeline development of its pharmaceutical drug candidates, support commercial sales of rare cannabinoids through its subsidiary BayMedica LLC, and for general working capital purposes.

    The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act") and Regulation D promulgated thereunder and, along with the common shares underlying the short-term preferred investment options sold in the offering, have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the unregistered securities to be issued in the offering (the "Resale Registration Statement").

    The Company also has agreed to amend certain existing preferred investment options to purchase up to an aggregate of 199,115 common shares that were previously issued in October 2023 and have an exercise price of $16.60 per share, for $0.125 per amended preferred investment option, effective upon the closing of the offering, such that the amended preferred investment options will have a reduced exercise price of $2.436 per share.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    To learn more about INM-901, please visit the website at: https://www.inmedpharma.com/pharmaceutical/inm-901-for-alzheimers-disease/.

    About InMed:

    InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.

    Investor Contact:

    Colin Clancy
    Vice President, Investor Relations
    and Corporate Communications
    T: +1 604 416 0999
    E: [email protected]

    Cautionary Note Regarding Forward-Looking Information:

    This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: the closing of the offering; the use of the net proceeds of the offering; the filing of a registration statement by InMed with the SEC covering the resale of the unregistered securities issued in the offering and the exercise of the short-term preferred investment options prior to their expiration.

    Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, in Item 1A. of the Quarterly Report for the period ended March 31, 2025, and other filings with the Securities and Exchange Commission on www.sec.gov.

    All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256740

    Get the next $INM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INM

    DatePrice TargetRatingAnalyst
    11/29/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $INM
    SEC Filings

    See more
    • InMed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

      6/30/25 4:16:01 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

      6/24/25 2:35:40 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Changes in Registrant's Certifying Accountant, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

      6/13/25 4:30:07 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hull Andrew bought $14,625 worth of shares (37,500 units at $0.39), increasing direct ownership by 4,947% to 38,258 units (SEC Form 4)

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      2/22/24 1:38:46 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adams Eric A bought $14,922 worth of shares (41,600 units at $0.36), increasing direct ownership by 1,763% to 43,959 units (SEC Form 4)

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      2/21/24 2:58:17 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hull Andrew

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      2/3/25 8:49:05 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sr VP & General Manager Johnson Shane Aaron

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      12/23/24 9:28:12 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Jagpal Netta

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      12/23/24 9:26:50 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on InMed Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $6.00

      11/29/21 6:20:24 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital reiterated coverage on InMed Pharmaceuticals with a new price target

      Roth Capital reiterated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $11.50 from $12.00 previously

      2/16/21 11:09:34 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

      Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-t

      6/27/25 7:00:00 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

      Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-term preferred

      6/25/25 8:00:00 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

      Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/GroSignificantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegenerationReduces key pro-inflammatory markers, independent of amyloid beta or tau pathologyVancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of n

      6/24/25 7:00:00 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INM
    Financials

    Live finance-specific insights

    See more
    • InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022

      VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022. Conference Call & Webcast:Friday, September 23, 2022, at 10:00 AM Pacific Time, 01:00 PM Eastern TimeRegistration Link: https://register.vevent.com/register/BIa76ceda464264b3cae0b5ddb6e76a511Webcast Link: https://edge.media-server.com/mmc/p/cnawzqhu(Webcast replay available for 12 months) To access the call by phone, please go to the registration link, and you will be provided w

      9/19/22 6:00:00 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update

      Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseasesCommercial rollout of an additional rare cannabinoid, CBT- first of several rare cannabinoid launches planned for the first half of 2022Advanced the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases VANCOUVER, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the development, manufacturing and commercialization of rare cannabinoids,

      2/14/22 7:34:02 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022

      VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will report financial results on Tuesday, February 15, 2022 for the second quarter of fiscal year 2022, ending December 31, 2021. Conference Call & Webcast*:Tuesday, February 15, 2022, at 11:00 AM Pacific Time, 02:00 PM Eastern TimeUS/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745US/CANADA Participant International Dial-In Number: +1 (914) 987-7959Conference ID: 8645175Webcast: https://edge.media-server.com/mmc/p/sa6ykfmv (*Webcast replay available

      2/10/22 7:30:00 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc.

      SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)

      11/14/24 4:36:01 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by InMed Pharmaceuticals Inc.

      SC 13G - InMed Pharmaceuticals Inc. (0001728328) (Subject)

      11/12/24 1:44:16 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc. (Amendment)

      SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)

      2/14/24 2:28:27 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INM
    Leadership Updates

    Live Leadership Updates

    See more
    • InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

      VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the Company has entered into a service contract (the "Contract") with Brio Financial Group ("Brio") to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022. Brio is a financial and management consulting group based in Bridgewater, New Jersey. The firm provid

      12/12/22 6:47:35 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed Announces Changes to its Board of Directors

      VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately. Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets.  Throughout her career, Ms. Lemerond has worked with public

      8/9/22 7:30:00 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed Announces Appointment of Chief Operating Officer

      VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces Michael Woudenberg has been appointed Chief Operating Officer of the Company, overseeing all day-to-day operations. Mr. Woudenberg was previously Senior Vice President of Chemistry, Manufacturing and Controls. Mike has been an integral part of the executive team for the last four years, supporting multiple functions within the organisation. Prior to joining InMed, Mike had over 20 years of successful drug development, process engineering, GMP manufa

      7/18/22 7:30:00 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care